vs

Side-by-side financial comparison of INVO Fertility, Inc. (IVF) and XTI Aerospace, Inc. (XTIA). Click either name above to swap in a different company.

XTI Aerospace, Inc. is the larger business by last-quarter revenue ($2.5M vs $1.8M, roughly 1.4× INVO Fertility, Inc.). INVO Fertility, Inc. runs the higher net margin — -150.5% vs -541.3%, a 390.8% gap on every dollar of revenue. On growth, XTI Aerospace, Inc. posted the faster year-over-year revenue change (170.6% vs 22.6%). INVO Fertility, Inc. produced more free cash flow last quarter ($-1.8M vs $-8.4M).

INVO Fertility, Inc. is a specialized healthcare company focused on delivering accessible assisted reproductive technology solutions. It develops, manufactures and markets the patented INVOcell intravaginal culture system for in vitro fertilization procedures, serving fertility clinics and patients across North America, Europe and other global regions, with a mission to reduce barriers to high-quality fertility care.

Nextant Aerospace is a United States–based company specializing in the remanufacturing of business jets. Founded in 2007, Nextant is the first company to introduce the concept of aircraft remanufacturing to the business jet market.

IVF vs XTIA — Head-to-Head

Bigger by revenue
XTIA
XTIA
1.4× larger
XTIA
$2.5M
$1.8M
IVF
Growing faster (revenue YoY)
XTIA
XTIA
+148.0% gap
XTIA
170.6%
22.6%
IVF
Higher net margin
IVF
IVF
390.8% more per $
IVF
-150.5%
-541.3%
XTIA
More free cash flow
IVF
IVF
$6.6M more FCF
IVF
$-1.8M
$-8.4M
XTIA

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
IVF
IVF
XTIA
XTIA
Revenue
$1.8M
$2.5M
Net Profit
$-2.6M
$-13.4M
Gross Margin
43.4%
Operating Margin
-93.1%
-596.2%
Net Margin
-150.5%
-541.3%
Revenue YoY
22.6%
170.6%
Net Profit YoY
-62.2%
-203.2%
EPS (diluted)
$-0.77
$-0.61

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVF
IVF
XTIA
XTIA
Q3 25
$1.8M
$2.5M
Q2 25
$1.9M
$600.0K
Q1 25
$1.6M
$484.0K
Q4 24
$1.7M
$1.0M
Q3 24
$1.4M
$918.0K
Q2 24
$1.8M
$1.0M
Q1 24
$1.6M
Q4 23
$1.4M
Net Profit
IVF
IVF
XTIA
XTIA
Q3 25
$-2.6M
$-13.4M
Q2 25
$-5.3M
$-20.9M
Q1 25
$-17.4M
$-12.9M
Q4 24
$-3.6M
Q3 24
$-1.6M
$-4.4M
Q2 24
$-2.2M
$-14.7M
Q1 24
$-1.6M
Q4 23
$-2.0M
Gross Margin
IVF
IVF
XTIA
XTIA
Q3 25
43.4%
Q2 25
80.5%
Q1 25
35.2%
69.2%
Q4 24
41.4%
54.7%
Q3 24
31.0%
56.6%
Q2 24
53.1%
64.2%
Q1 24
45.3%
Q4 23
33.0%
Operating Margin
IVF
IVF
XTIA
XTIA
Q3 25
-93.1%
-596.2%
Q2 25
-160.4%
-1855.0%
Q1 25
-1042.1%
-2149.2%
Q4 24
-202.0%
Q3 24
-90.7%
-459.3%
Q2 24
-100.9%
-1350.8%
Q1 24
-95.7%
Q4 23
-109.2%
Net Margin
IVF
IVF
XTIA
XTIA
Q3 25
-150.5%
-541.3%
Q2 25
-283.6%
-3476.3%
Q1 25
-1060.1%
-2659.5%
Q4 24
-211.3%
Q3 24
-113.8%
-483.1%
Q2 24
-122.2%
-1426.8%
Q1 24
-101.3%
Q4 23
-144.4%
EPS (diluted)
IVF
IVF
XTIA
XTIA
Q3 25
$-0.77
$-0.61
Q2 25
$-13.30
$-2.93
Q1 25
$-12.53
$-3.80
Q4 24
$14.86
Q3 24
$-15.11
$-33.40
Q2 24
$-22.39
$-261.99
Q1 24
$-7.55
Q4 23
$-59.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVF
IVF
XTIA
XTIA
Cash + ST InvestmentsLiquidity on hand
$32.2M
Total DebtLower is stronger
$2.0M
Stockholders' EquityBook value
$5.8M
$10.5M
Total Assets
$18.8M
$47.9M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVF
IVF
XTIA
XTIA
Q3 25
$32.2M
Q2 25
$20.0M
Q1 25
$8.0M
Q4 24
$4.0M
Q3 24
$511.0K
Q2 24
$5.8M
Q1 24
Q4 23
Total Debt
IVF
IVF
XTIA
XTIA
Q3 25
$2.0M
Q2 25
$4.8M
$65.0K
Q1 25
$65.0K
Q4 24
$7.5M
$65.0K
Q3 24
Q2 24
Q1 24
Q4 23
Stockholders' Equity
IVF
IVF
XTIA
XTIA
Q3 25
$5.8M
$10.5M
Q2 25
$2.6M
$12.4M
Q1 25
$3.3M
$13.9M
Q4 24
$12.7M
$6.6M
Q3 24
$-23.3K
$6.9M
Q2 24
$1.4M
$10.6M
Q1 24
$10.2K
Q4 23
$892.8K
Total Assets
IVF
IVF
XTIA
XTIA
Q3 25
$18.8M
$47.9M
Q2 25
$19.3M
$35.4M
Q1 25
$31.7M
$27.1M
Q4 24
$46.4M
$24.3M
Q3 24
$17.0M
$29.3M
Q2 24
$17.8M
$34.0M
Q1 24
$17.3M
Q4 23
$18.5M
Debt / Equity
IVF
IVF
XTIA
XTIA
Q3 25
0.34×
Q2 25
1.83×
0.01×
Q1 25
0.00×
Q4 24
0.59×
0.01×
Q3 24
Q2 24
Q1 24
Q4 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVF
IVF
XTIA
XTIA
Operating Cash FlowLast quarter
$-1.8M
$-8.4M
Free Cash FlowOCF − Capex
$-1.8M
$-8.4M
FCF MarginFCF / Revenue
-101.6%
-338.0%
Capex IntensityCapex / Revenue
0.5%
0.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-7.8M
$-52.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVF
IVF
XTIA
XTIA
Q3 25
$-1.8M
$-8.4M
Q2 25
$-1.7M
$-6.7M
Q1 25
$-3.5M
$-15.2M
Q4 24
$-617.4K
$-22.3M
Q3 24
$-640.8K
$-6.1M
Q2 24
$-1.5M
$-5.6M
Q1 24
$-260.6K
Q4 23
$-714.9K
Free Cash Flow
IVF
IVF
XTIA
XTIA
Q3 25
$-1.8M
$-8.4M
Q2 25
$-1.7M
$-6.8M
Q1 25
$-3.6M
$-15.3M
Q4 24
$-696.3K
$-22.4M
Q3 24
$-6.2M
Q2 24
$-1.5M
$-5.7M
Q1 24
$-310.3K
Q4 23
FCF Margin
IVF
IVF
XTIA
XTIA
Q3 25
-101.6%
-338.0%
Q2 25
-92.6%
-1133.2%
Q1 25
-216.9%
-3158.5%
Q4 24
-40.6%
-2166.0%
Q3 24
-670.0%
Q2 24
-82.3%
-548.0%
Q1 24
-19.7%
Q4 23
Capex Intensity
IVF
IVF
XTIA
XTIA
Q3 25
0.5%
0.9%
Q2 25
0.5%
9.7%
Q1 25
0.9%
9.3%
Q4 24
4.6%
6.6%
Q3 24
0.0%
3.9%
Q2 24
3.0%
1.1%
Q1 24
3.2%
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IVF
IVF

Segment breakdown not available.

XTIA
XTIA

Short Term Contract With Customer$2.1M85%
Other$374.0K15%

Related Comparisons